OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
February 17, 2021
The EC has granted marketing authorization to Celltrion Healthcare for its adalimumab biosimilar, Yuflyma (CT-P17).
December 11, 2020
Celltrion Healthcare has announced that EMA's CHMP has issued a positive opinion for the marketing authorization of CT-P17—an adalimumab biosimilar.
October 30, 2020
The Center for Drug Evaluation and Research is studying factors that influence the development of generic versions of brand-name drugs.
October 02, 2020
Advances in preclinical development play a crucial role in reducing cost for developing biosimilars.
August 13, 2020
The company has launched its biosimilar rituximab, Ritucad, for the Indian market.
The committee has given a positive opinion on the biosimilar bevacizumab for several cancer indications.
The companies received approval from the EC for Zercepac (HLX02), a biosimilar referencing Roche’s originator biologic, Herceptin (trastuzumab).
July 01, 2020
Appropriate analytical assays are needed to determine and ensure that biosimilar critical quality parameters are on track.
May 05, 2020
FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.
April 08, 2020
Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.